Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 17

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome31Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Dry age-related macular degeneration16Rhinitis allergic16Diabetic retinal oedema13Dry eye12Age-related macular degeneration11Retinitis pigmentosa11Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Neuromyelitis optica spectrum disorder6+114

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Conjunctivitis allergic+1

Not recruiting

Dose‑finding trial of a mannan‑conjugated Phleum pratense/Dactylis glomerata allergoid vaccine in patients with grass‑pollen allergic rhinitis or rhinoconjunctivitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Bilastine
  • Sponsor:Inmunotek S.L.

Choroidal neovascularisation

Not recruiting

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Diabetic retinal oedema

Not recruiting

A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Diabetic retinal oedema

Not recruiting

A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Uveitis

Not recruiting

A study to evaluate the safety of REGN7041 in adults with active noninfectious uveitis affecting the back of the eye.

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Regeneron Pharmaceuticals Inc.

Seasonal allergy

Not recruiting

Effect of a single oral dose of acalabrutinib on skin prick test wheal size in adults with grass pollen allergy using histamine dihydrochloride and phleum pratense

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Alk-Abello A/S

Conjunctivitis allergic

Not recruiting

Study of bilastine for effectiveness, safety and quality of life in children aged 6 to 12 years with allergic rhinoconjunctivitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bilastine
  • Sponsor:A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Conjunctivitis allergic+1

Not recruiting

Testing sublingual immunotherapy with dermatophagoides pteronyssinus extract for adults with moderate to severe house dust mite allergy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dermatophagoides Pteronyssinus Extract
  • Sponsor:ROXALL Medizin GmbH

Systemic scleroderma+3

Not recruiting

A Study of Cizutamig for Patients with Severe Autoimmune Inflammatory Diseases That Did Not Respond to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Neovascular age-related macular degeneration

Not recruiting

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.

Glaucoma

Not recruiting

Comparison of Dexamethasone and Diclofenac Eye Drops After Glaucoma Surgery in Patients with Medically Uncontrolled Glaucoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Sodium
  • Sponsor:Rigshospitalet

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.